Yongxiang Xia
No. 300 Guangzhou Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Colorectal Cancer Cell's Weapon: RNF32 Engages SPP1+ Macrophages to Foster Liver Metastasis, Targeted by Indole-3-Acetic Acid.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 06, 2025
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing.
Journal: Cell death & disease
Published: October 06, 2023
Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Journal: Journal of gastrointestinal oncology
Published: July 17, 2023
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
Journal: Alimentary pharmacology & therapeutics
Published: May 14, 2023
The Ninj1/Dusp1 Axis Contributes to Liver Ischemia Reperfusion Injury by Regulating Macrophage Activation and Neutrophil Infiltration.
Journal: Cellular and molecular gastroenterology and hepatology
Published: July 17, 2022
CCAAT/Enhancer-binding Protein Homologous Protein Promotes ROS-mediated Liver Ischemia and Reperfusion Injury by Inhibiting Mitophagy in Hepatocytes.
Journal: Transplantation
Published: July 13, 2022
Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study.
Journal: Frontiers in oncology
Published: June 10, 2022
Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Journal: International journal of biological sciences
Published: April 13, 2022
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
Journal: Frontiers in oncology
Published: March 31, 2022
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
Journal: Frontiers in immunology
Published: February 15, 2022
Last Updated: 09/26/2026